期刊文献+

轮状病毒规模化纯化方法的建立 被引量:3

Development of a method for large-scale purification of rotavirus
原文传递
导出
摘要 目的建立一种可规模化纯化轮状病毒(Rotavirus,RV)的方法。方法以氯化铯密度梯度离心法(离心法)纯化RV作为对照,分析采用离心-微滤-超滤-层析法(模块法)纯化RV的可行性。透射电镜观察病毒形态;微量滴定法测定病毒的感染性滴度;Bradford法检测纯化前后病毒液的蛋白含量,计算蛋白回收率;以两种方法纯化的病毒免疫BALB/c小鼠,微量中和试验检测小鼠血清中和抗体滴度。结果模块法纯化的RV结构完整,感染性滴度可达(7.15±0.10)lgCCID50,可清除超过95%的蛋白质,蛋白回收率为(2.58±0.06)%,免疫小鼠可诱导中和抗体。模块法纯化的RV蛋白回收率、感染性滴度及诱导的小鼠中和抗体水平均显著高于离心法(P<0.05或P<0.01)。结论模块法可有效纯化RV,为RV灭活疫苗规模化纯化工艺的开发提供了实验依据。 Objective To develop a method for large-scale purification of rotavirus (RV). Methods The feasibility of centrifugation-microfiltration-uhrafiltration-chromatography (module method) for purification of RV was evaluated using cesium chloride density gradient centrifugation as control. R~ was observed for morphology by transmission electron microscopy, then determined for infectious titer by microtitration method, and for protein contents before and after purification by Bradford method, based on which the recovery rate of protein was calculated. BALB / c mice were immunized with RV purified by the two methods, and determined for neutralizing antibody titer in sera by micro-neutralization assay. Results RV purified by module method showed intact structure, of which the infectious titer reached (7. 15 +- O. 10) lgCCIDs0. More than 95% of protein was removed, and the recovery rate of protein was (2. 58 + 0. 06)%. The purified RV induced neutralizing antibody titer in mice. However, the recovery rate of protein, infectious titer and the induced neutralizing antibody titer of the RV purified by module method were significantly higher than those by cesium chloride density gradient centrifugation (P 〈 0. 05 or P 〈 O. 01 ). Conclusion The developed module method may be used ibr effective purification of RV, which provides an experimental basis for development of procedure for large- scale purification of inactivated RV vaccine.
出处 《中国生物制品学杂志》 CAS CSCD 2012年第4期480-482,491,共4页 Chinese Journal of Biologicals
基金 国家863计划资助项目(2006AA02A211) 广东医学院科研基金博士启动项目资助(2011)
关键词 轮状病毒疫苗 纯化 层析 Rotavirus vaccine Purification Chromatography
  • 相关文献

参考文献9

  • 1Parashar UD,Gibson CJ,Bresse JS. Rotavirus and severe childhood diarrhea[J].Emerging Infectious Diseases,2006,(02):304-306.
  • 2Nelson EA,Bresee JS,Parashar UD. Rotavirus epidemiology:the Asian rotavirus surveillance network[J].Vaccine,2008,(26):3192-3196.doi:10.1016/j.vaccine.2008.03.073.
  • 3Parashar UD,Burton A,Lanata C. Global mortality asssociated with rotavirus disease among children in 2004[J].Journal of Infectious Diseases,2009,(Suppl 1):S9-S15.
  • 4Jiang B,Estes MK,Barone C. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles[J].Vaccine,1999,(7-8):1005-1013.doi:10.1016/S0264-410X(98)00317-X.
  • 5Zhang B,Yi S,Ma Y. Immunogenicity of a scalable inactivated rotavirus vaccine in mice[J].Hum Vaccin,2011,(02):248-257.
  • 6Peixoto C,Sousa MF,Silva AC. Downstream processing of triple layered rotavirus like particles[J].Journal of Biotechnology,2007,(03):452-461.
  • 7Gorrell RJ,Bishop RF. Homotypic and heterotypic serum neutralizing antibody response to rotavirus proteins following natural primary infection and reinfection in children[J].Journal of Medical Virology,1999,(02):204-211.doi:10.1002/(SICI)1096-9071(199902)57:2&lt;204::AID-JMV20&gt;3.0.CO;2-Y.
  • 8Johansen K,Schroder U,Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants[J].Vaccine,2003,(5-6):368-375.doi:10.1016/S0264-410X(02)00617-5.
  • 9Wang Y,Azevedo M,Saif LJ. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets[J].Vaccine,2010,(33):5432-5436.

同被引文献42

  • 1吴浩飞,杨晓明,黄仕和.Vero细胞作为基质的病毒性疫苗研制进展[J].微生物学免疫学进展,2011,39(3):56-63. 被引量:5
  • 2谢忠平,宋霞,李文忠,熊秋霞,李华,崔萍芳,全文琦,丁雪凤.氯仿抽提细胞培养物中纯化甲肝病毒[J].中国公共卫生,2004,20(3):298-299. 被引量:5
  • 3方肇寅,张丽杰,唐景裕,章青,胡海宽,谢华萍,郑丽舒,Duncan Steele,Paul Kilgore,Joseph Bresee,Erik Hummelman,Xi Jiang,Roger Glass.中国河北省卢龙县儿童轮状病毒腹泻研究[J].病毒学报,2005,21(1):21-26. 被引量:40
  • 4Ruiz-Palacios G M, Prez-Schael I, Vel6zquez F R, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med, 2006, 354 (1) : 11-22.
  • 5Vesikari T, Matson D O, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine ( WC3 ) reassortant rotavirus vaccine. N Engl J Med, 2006, 354 (1) : 23- 33.
  • 6Fu C, Wang M, Liang J, et al. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization : a matched case-control study. Vaccine, 2007,25 (52) : 8756-8761.
  • 7Centers for Disease Control and Prevention (CDC).Intussusception among recipients of rotavirus vaccine-United States, 1998 -1999. Morb Mortal Wkly Rep, 1999, 48 (27) : 577-581.
  • 8Buttery J P, Danchin M H, Lee K J, et al. Intussusception following rotavirus vaccine administration : post-marketing surveillance in the national immunization program in Australia. Vaccine, 2011, 29 (16): 3061-3066.
  • 9Patel M M, Lpez-Collada V R, Bulhes M M, et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med, 2011,364 (24) : 2283-2292.
  • 10Velazquez F R, Colindres R E, Grajales C, et al. Postmarketing urveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis I, 2012, 31 (7) : 736-744.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部